Symphony Ltd Q4 FY2026 Concall Summary

Key Takeaways

• A brutal year, cleaned up in one quarter: Consolidated revenue fell 28% YoY to ₹1,131 crores, and the company posted a ₹141 crore PAT loss after impairing its entire ₹348 crore Australian equity investment. The reset is now complete, and management draws a line under it.
• The Australia drag is removed: The Board categorically ruled out further capital allocation to Australia, impaired the full investment, and is shifting the subsidiary to a capital-light distributor model. The business had lost ₹60 crores over two years.
• Core India business hit by channel destocking and a bad summer: Q4 India revenue halved to ₹199 crores from ₹368 crores, partly due to a high base of unbilled advances and cautious channel inventory after the 2025 summer failure.
• Gross margins held, but operating leverage bit hard: Consolidated gross margin stayed resilient at 46.4%, yet Q4 EBITDA margin compressed to 15.5% from 21.2% as fixed costs spread over a much smaller revenue base.
• What to watch next quarter: Whether the 4–6 week summer sales window from mid-May actually delivers, the pace of the July 1 cost pass-through, and any early sign that the round-the-year portfolio is scaling toward management’s margin ambition.

The Australia Reset

• Thesis failure acknowledged: The 2018 acquisition did not translate financially due to COVID lockdowns (21 months within 15–16 months of closing) and a regulatory shift that forced an exit from gas-based products. Despite halving overheads, switching to an outsourced model, and expanding marketing, Australia lost ₹33 crores in FY26 alone.
• Full impairment taken: The Board impaired the entire ₹348 crores of equity (₹298 crores this year plus ₹50 crores last year). At the consolidated level, the charge was ₹259 crores including goodwill, intangible assets and deferred tax.
• No more money: The Board categorically decided no further capital investment or allocation to Australia. A ₹165 crore infusion in March repaid long-term and working capital loans guaranteed by Symphony India, and that is the last cheque.
• Distributor model replaces direct operations: The subsidiary will stop warehousing and distributing directly. Distributors will invest, buy products from India or China, warehouse them, and sell to local dealers. The subsidiary retains only a team to manage affairs, replicating the Brazil model.
• Cost base shrinks further: Current cost of doing business is ~₹500K–600K per month and will fall once warehousing costs are eliminated.

Nrupesh Shah: "We must accept that our original acquisition thesis of Australia business has not translated into the financial outcome due to external situation and despite making all around turnaround efforts."

India Business & Summer Outlook

• Q4 collapse was partly technical: India revenue of ₹199 crores compared to ₹368 crores a year ago. The base quarter had large unbilled advances as of December 31, and some billing was extended into the next quarter. Channel caution from inventory overhang and the failed 2025 summer compounded the drop.
• Summer 2026 is a 4–6 week bet: The season started in the third week of March with decent performance in South, West and parts of Central India through April. North and East channel inventories are largely rationalized. Weather disturbances hit in April, but management expects a decent summer from mid-May, giving a runway of 4 to 6 weeks of meaningful sales.
• Management will not quantify the upside: When asked for a double-digit growth forecast, management deflected, saying it would need a precise multi-week weather forecast to make that call.

Subsidiary Health Beyond Australia

• USA ring-fenced and derisked: Bonaire USA equity was bought by Symphony India for ₹30 crores, and IPRs including the Bonaire brand for ~₹23 crores, totaling ~₹52 crores from the India treasury. Proceeds repay the remaining working capital loan guaranteed by Symphony India. US sales were ~₹45 crores in FY26 against a potential of at least ₹140 crores, with EBITDA margins in line with the domestic business.
• GSK China performing and repaying: Delivered decent top-line and profitability growth. Repaid ₹26 crores to Symphony India, reducing the net loan to ₹4 crores from a peak of over ₹60 crores. Expected to be debt-free within six months.
• IMPCO Mexico flat but clean: Revenue was flattish with a channel inventory overhang. Mexico and China have negligible equity deployment and are capital accretive.
• Tariffs a non-issue: By the time products reached US shores, the tariff from India had dropped to ~12%; from Mexico there is no tariff.

Portfolio Diversification & New Categories

• BISP now half the company: Beyond India Summer Products (large space ventilated air cooling, tower fans, kitchen fans, water heaters, exports, overseas subsidiaries) constituted 49% of FY26 consolidated revenue, providing product and geographical diversification.
• BISP margins are decent and have room: Despite substantial ad and sales promotion spend over 3–4 years, BISP EBITDA is at a high-single-digit margin percentage. Large space ventilated cooling EBITDA margin already exceeds the residential air cooler category.
• Round-the-year portfolio is a margin story in progress: Standalone and consolidated EBITDA for this portfolio is high single-digit, held back by intentional one-time costs in trade channel build, advertising, and launch expenses. Management sees potential to match air cooler margins with operating leverage.
• Water heater launch is early and differentiated: Launched in FY26 in very limited markets with insignificant revenue. The product carries a unique proposition: a hair fall control geyser that no competitor offers. Geographical spread widens this year, but management calls it a long-haul build.

Achal Bakeri: "We have a unique product proposition in terms of the hair fall control geyser, which is something no other competitor in the industry has."

Margins & Cost Management

• Gross margin held the line: Consolidated gross margin stayed at ~46%, in line with the prior year, despite major turmoil and summer disturbances. No pricing pressure materialized despite cost pressure, aided by a variety of strategies.
• Operating leverage drove the EBITDA hit: Q4 consolidated EBITDA margin fell to 15.5% from 21.2%, overwhelmingly due to economies of scale and operating leverage on the shrunken revenue base.
• Other expenses rose on cost pressures: A significant increase in other expenses reflected input cost pressure. The June quarter benefits from old inventory carried at lower cost.
• Price pass-through coming July 1: Management stated that starting July 1, as fully new production cycles take over, the company will be in a position to pass the entire price increase in one way or another.

Nrupesh Shah: "As fully new production takes place and starting 1st July, we will be in a position to pass entire price increase in one way or other way."

Capital Allocation & Shareholder Returns

• Dividend maintained despite the loss: The Board declared a final dividend of ₹5 per share on a face value of ₹2, taking the total annual payout to ₹62 crores.
• Buyback talk deflected: When pressed twice on a share buyback given the low stock price, management first said no buyback is planned, then offered a vague "at the right time, Board will consider as it was done in the past." They framed the Australia and USA buybacks as de facto capital return. No timeline or commitment was given.
• Australia equity written to zero: The ₹348 crore cumulative equity investment is fully impaired. The Board’s categorical decision means no further capital allocation, full stop.

Guidance & Commitments

Key Metrics